Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 3/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965296 | 0.93 | PIK3CD (0.52) | PIK3CDPIK3CAPIM1PIM2PIM3 | |
| SCHEMBL8036551 | 0.91 | PIK3CD (0.51) | PIK3CDPIK3CAPIM1PIM2PIM3 | |
| SCHEMBL13294661 | 0.89 | HPGDS (0.51) | PIK3CDPIK3CAPIM1PIM2PIM3 | |
| SCHEMBL29641671 | 0.84 | PIK3CD (0.49) | PIK3CDPIK3CAPIM1PIM2PIM3 | |
| SCHEMBL4879777 | 0.80 | PIK3CD (0.42) | PIK3CDPIK3CAUSP30 | |
| SCHEMBL29620532 | 0.76 | AURKA (0.63) | MAPTKMT2AKDM4EMEN1NPC1 | |
| SCHEMBL190954 | 0.76 | AURKA (0.63) | MAPTKMT2AKDM4EMEN1NPC1 | |
| SCHEMBL20691472 | 0.76 | MEN1 (0.56) | MAPTKMT2AKDM4EMEN1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL20267253 | 0.74 | AURKA (0.61) | MAPTKMT2AKDM4EMEN1NPC1 | |
| Hydrochloric Acid SCHEMBL8889589 | 0.74 | KMT2A (0.40) | PIK3CDPIK3CAPIM1PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9913831-B2 | Methods and compositions for treating nephrogenic diabetes insipidus | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2018-03-13 | — | — | US | disclosed |
| EP-2750676-B1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | UNIV UTAH RES FOUND (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9539246-B2 | Methods and compositions for treating nephrogenic diabetes insipidus | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160296504-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | UNIVERSITY OF UTAH | 2016-10-13 | — | — | US | disclosed |
| US-20140377380-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-25 | — | — | US | disclosed |
| CN-101998953-B | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2014-12-17 | — | — | CN | disclosed |
| CN-101998953-B | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2014-12-17 | — | — | CN | disclosed |
| CN-101998953-B | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2014-12-17 | — | — | CN | disclosed |
| EP-2750676-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | University Of Utah Research Foundation (US) | 2014-07-09 | — | — | EP | disclosed |
| JP-5374578-B2 | — | — | 2013-12-25 | — | — | JP | disclosed |
| EP-2283011-B1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-11-23 | — | — | EP | disclosed |
| CN-101998953-A | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-03-30 | — | — | CN | disclosed |
| CN-101998953-A | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-03-30 | — | — | CN | disclosed |
| CN-101998953-A | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-03-30 | — | — | CN | disclosed |
| EP-2283011-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-16 | — | — | EP | disclosed |
| EP-2283011-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20110028484-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| US-20110028484-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| WO-2009125365-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125365-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296504-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | GPR119, SLC5A2, P2RY2 | PIK3CD 484/4885PIK3CA 299/4885PIM1 4053/4885 |
| US-20110028484-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | P2RY12, P2RY13, P2RY4 | PIK3CD 656/4885PIK3CA 207/4885PIM1 2761/4885 |
| US-20140377380-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | GPR119, SLC5A2, P2RY2 | PIK3CD 484/4885PIK3CA 299/4885PIM1 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.